In recent years, Alzheimer’s treatments have largely focused on slowing disease progression, but a new study points to a more ambitious possibility. Research conducted by Case Western Reserve University and affiliated centers reports that an experimental drug candidate reduced markers of brain damage and improved cognitive performance in mice modeling Alzheimer’s disease.
In Alzheimer’s disease, levels of NAD+, a critical molecule that helps maintain the brain’s energy balance, decline over time. This decrease disrupts cellular energy metabolism, impairs DNA repair mechanisms, and leads to increased oxidative stress and inflammation. The researchers showed that this breakdown in energy balance becomes more pronounced as Alzheimer’s progresses and may be one of the key drivers of the disease.
In the study, the research team used a synergistic compound known as P7C3-A20 to restore NAD+ balance in the brain. By preventing excessive breakdown of NAD+, the compound helped preserve intracellular energy homeostasis, allowing brain cells to regain function. In Alzheimer’s model mice, the treatment not only slowed disease progression but also led to a marked improvement in existing brain damage.
Following treatment, the mice showed recovery in cognitive functions, increased synaptic activity, and improved integrity of the blood–brain barrier. Researchers also observed a significant reduction in levels of phosphorylated tau 217, a biomarker associated with Alzheimer’s disease. Together, these findings point to a potential shift in treatment goals, from merely preventing or slowing the disease to possibly reversing damage even at advanced stages.
Lead author Andrew A. Pieper emphasized that while the results are encouraging, they have so far been obtained only in animal models. He stressed that carefully controlled clinical trials are needed to evaluate the safety and effectiveness of the approach in humans.
Source: Medical News Today
